TAK: 武田制药

TAK新闻

• 17:02 Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
• 18:46 A New Look At Legend Biotech: Plenty Of Upside For Carvykti (NASDAQ:LEGN)
• 18:05 Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
• 18:05 DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
• 15:15 PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
• 13:44 Ascendis Pharma Stock: Behind The Stock Surge (NASDAQ:ASND)
• 12:40 Denali to Sell Priority Review Voucher for $195M Cash Boost
• 19:27 Takeda Pharmaceutical: The Downside Was Forecastable (NYSE:TAK)
• 13:51 Takeda Designed A Psoriasis Pill Using AI. It Just Walloped Bristol's Sotyktu In A Head-To-Head Test.
• 18:58 Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
• 16:14 Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
• 16:13 Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
• 06:09 Takeda Pharmaceutical Company Limited (TAK) Q4 FY2025 Earnings Call Transcript
• 18:30 Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
• 10:29 Takeda's Rich Pipeline Optionality Is Worth A 'Buy' (NYSE:TAK)
• 16:40 Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript
• 16:36 DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
• 14:37 Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
• 13:40 Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
• 18:21 ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
• 16:31 SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
• 15:37 Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
• 15:37 Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
• 17:38 DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?